Depression medications often lose their power as Parkinson’s and Alzheimer’s disease progress, a challenge rooted in how neurodegeneration alters brain chemistry itself.
Severe Tourette syndrome can devastate a person’s life—but deep brain stimulation offers meaningful symptom reduction when other treatments have failed.
Healthcare providers trained in Parkinson’s mental health recognize depression, anxiety, and apathy as treatable dimensions of disease care.
Transdermal patches deliver tremor medication continuously through the skin, potentially offering steadier symptom control than daily pills with fewer dose-related side effects.
A $6 million grant to Banner Sun Health accelerates the development of blood tests that could identify Parkinson’s disease earlier than current clinical methods.
Phase 1b/2a trial enrollment completion signals progress in evaluating RNDP-001, but approval remains years away.
Scientists are investigating whether restoring healthy gut bacteria could slow or prevent Parkinson’s disease.
FDA approval of new delivery methods and dozens of emerging Parkinson’s therapies in clinical trials are reshaping treatment options in 2026.
A major 2026 Mexican study identified 32 genetic variants linked to Parkinson’s disease, shifting understanding of genetic risk in understudied populations.
Early Parkinson’s diagnosis unlocks years of independence that cannot be reclaimed once lost to unrecognized disease progression.